why is there a hold on LL? It is because the FDA has no

New Post Public Reply Private Reply Replies (2) Message Board
MGK_2 Drano #135134
957
why is there a hold on LL? It is because the FDA has no proof that it is safe.
In their eyes, it could be very dangerous. They didn't go on here-say, they go on data which they never got from Amarex. So they were told by Amarex that it is safe. There were no incidents for many years. So the trials continued.

Until those 2 cardiac SAEs in the Brazil trial which led to the hold.

So what will lifting the hold do? Yes, it will allow LL to be used in trials. But, it will do far more. In essence, it becomes a declaration from the FDA that LL is clinically and scientifically safe. When they lift the hold, they say that LL is safe and they will stand by that until another Serious Adverse Event occurs.

In order to get approval, you need a declaration of Safety from FDA, that the drug is safe. Lifting the hold is that declaration. All the work CytoDyn did to scientifically prove that LL is safe was by essentially re-writing the BLA for HIV MDR. That BLA has been, for the most part, re-written. Lifting the hold, is akin to accepting that BLA for approving purposes.

This is not to say that CytoDyn will re-submit the BLA, but they could really, since it really is finished. I believe there were some issues in collection of the primary endpoints and that may be part of the reason why the FDA wants a re-write on the protocol for HIV trials as there may be an issue with how the primary endpoint is obtained.

Maybe the FDA wants to see another endpoint...

No, I'm not suggesting that arbitration is delayed until LL is approved. Hopefully, only a short time period following lifting of the hold. Even a fourth or a fifth of a rightful rough estimate would be enormous and satisfactory by me.

If the FDA finds that in order to obtain approval for HIV, CytoDyn will have to do another trial with the new protocol, then what the heck was Amarex conducting a trial with a piss poor protocol in the first place for? More sabotage?

We now know LL is safe. We met p value by 16x. But the protocol was off?

1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 3

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 4

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
USPS Honors 150 Years of the U.S. Coast Guard Academy

Updated Category News Views 7

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Continue Reading
SMPL Faces Legal Drama: What Investors Need to Know

Updated Category News Views 5

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 5

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 3

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 3

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 4

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 4

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 5

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights Into December's Top Mobile and CTV Apps for Revenue

Updated Category News Views 170

Top Revenue Generating Mobile and CTV Apps for December 2024 The evolving landscape of mobile and Connected TV (CTV) applications continually captivates users and advertisers alike. As 2024 comes to a close, the spotlight shines on the highest-grossing apps in North America, specifically in the United States and Canada, revealing significant trends in user engagement and...

Continue Reading
LET Mining's Cloud Strategy for XRP: Earn Passive Income Today

Updated Category News Views 106

Introduction to LET Mining's New Approach LET Mining is making waves with its innovative strategy that leverages XRP for cloud mining. This fresh perspective has caught the attention of numerous XRP holders, sparking excitement about its long-term profit potential. As more users join the platform, LET Mining is focusing on refining its computing power allocation to...

Continue Reading
Understanding Recent Changes in American Intl Gr's Short Interest

Updated Category News Views 70

Understanding American Intl Gr's Short Interest Dynamics American Intl Gr (AIG) has recently seen a notable change in its short percent of float, which has decreased by 3.24% since the last report. This change reflects a current total of 10.23 million shares sold short, making up approximately 1.79% of all available shares for trading. With the current trading volume,...

Continue Reading
Exploring the Future of the Phosphate Market: Growth and Trends

Updated Category News Views 520

The Rising Phosphate Market: An Overview The phosphate market is experiencing remarkable growth, projected to soar to approximately $219.74 billion in the coming years, driven by an annual growth rate of 3.9%. This growth is closely linked to the rising global demand for agricultural fertilizers, which play a crucial role in providing essential nutrients for plants....

Continue Reading
Clene Inc. to Engage with Investors at Benchmark Conference

Updated Category News Views 108

Clene Inc. to Engage with Investors at Benchmark Conference Clene Inc. (Nasdaq: CLNN), a dynamic clinical-stage biopharmaceutical company, is making its mark in the healthcare industry by focusing on innovative solutions for neurodegenerative diseases. Their mission is clear: to enhance mitochondrial health and safeguard neuronal functions. With a commitment to tackling...

Continue Reading